SCHEMBL23701587

SCHEMBL23701587

COC(=O)NC(C)Cc1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.46
CTSV O60911 1/20 0.40
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
THRB P10828 1/20 0.39
TP53 P04637 2/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FLT1 P17948 3/20 0.38
KDR P35968 3/20 0.38
GSK3B P49841 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
DDX3X O00571 1/20 0.37
MGAM O43451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30463740 0.86 FLT1 (0.42) ABCG2TP53POLBKDM4EALDH1A1
SCHEMBL22556554 0.86 FLT1 (0.42) ABCG2TP53POLBKDM4EALDH1A1
SCHEMBL23701533 0.85 ABCG2 (0.48) ABCG2THRBTP53POLBKDM4E
SCHEMBL23701513 0.85 ABCG2 (0.47) ABCG2THRBTP53POLBKDM4E
SCHEMBL23701617 0.84 ABCG2 (0.46) ABCG2THRBTP53POLBKDM4E
SCHEMBL23701541 0.83 ABCG2 (0.46) ABCG2THRBTP53POLBKDM4E
SCHEMBL23701542 0.82 ABCG2 (0.43) ABCG2CTSVCTSBCTSSCTSK
SCHEMBL23701586 0.82 ABCG2 (0.41) ABCG2CTSVCTSBCTSSCTSK
SCHEMBL23701608 0.82 DDX3X (0.46) ABCG2THRBTP53POLBKDM4E
SCHEMBL22556394 0.81 ABCG2 (0.52) ABCG2THRBTP53POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 ABCG2 2985/4885CTSV 4249/4885CTSB 3886/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 ABCG2 2985/4885CTSV 4249/4885CTSB 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.